rpo tirzepatide Tirzepatide 5mg GIP/GLP-1 Receptor Agonist

The chemistry is the same everywhere

What were the key findings and safety outcomes of the STRIDE trial evaluating semaglutide in adults with type 2 diabetes and Fontaine IIa peripheral artery disease?

A patient who tolerates and maintains 7.5 mg long-term will see better results than one who escalates to 10 mg then stops due to side effects

In trials, Mounjaro has been shown to lead to weight loss of up to 21% to 22.5% at the highest dose, which is comparable to the weight loss achieved through bariatric surgery

This hypothesis, however, remains speculative and requires prospective validation in appropriately designed trials

For users who are switching from tirzepatide to semaglutide or vice versa, the conversion chart helps navigate the transition smoothly